oral glp 1 agonist for type 2 diabetes In the phase 3 ACHIEVE-1 trial, published in June 2025, the small-molecule GLP-1 receptor orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with FDA Approves Oral Semaglutide as

Chronic acid reflux can cause complications for your esophagus, such as heartburn and inflammation (esophagitis)

Kushner now sees that often inverted: the drug does the heavy lifting on appetite, and lifestyle becomes the thing that makes the result last

That remains less clear

Personalizing Treatment Based on DEXA Results Healthcare providers can use DEXA scan data to tailor GLP-1 treatment plans, including dietary, exercise, or medication adjustments to optimize body composition outcomes

Nevertheless, given the inability to ensure absence of long-term adverse effects for this novel therapy, clinicians should remain vigilant

Diabetes 63 , 41864196 (2014)